Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dayer

Showing results (81-90 of 163) with videos related to

Pageof 17
Sort By:
Biochemical Pharmacology|December 1, 1987
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiencyP Dayer, T Kronbach, M Eichelbaum, et al.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|February 4, 1992
[Therapy compliance. A matter of concern in clinical medicine]J Fabre, J P Assal, L Balant, et al.
British Journal of Clinical Pharmacology|January 1, 1996
Contribution of monoaminergic modulation to the analgesic effect of tramadolJ A Desmeules, V Piguet, L Collart, et al.
Schweizerische Medizinische Wochenschrift|October 16, 1982
[Prevalence of arterial hypertension according to national origin. Epidemiologic survey of the personnel of the international organizations in Geneva]P Laravoire, A Baczko, J Fabre, et al.
European Journal of Clinical Pharmacology|December 14, 1999
Drug-drug interactions of new active substances: mibefradil exampleJ C Krayenbühl, S Vozeh, M Kondo-Oestreicher, et al.
Cancer Research|December 16, 1998
Association between lung cancer and microsomal epoxide hydrolase genotypesS Benhamou, M Reinikainen, C Bouchardy, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolP Dayer, L Balant, A Kupfer, et al.
European Journal of Clinical Pharmacology|January 1, 1983
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agentsP Dayer, L Balant, A Küpfer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Metabolic genetic polymorphisms and susceptibility to lung cancerC Bouchardy, S Benhamou, N Jourenkova, et al.
Pharmaceutica Acta Helvetiae|January 1, 1982
[Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency]D Dupont, P Dayer, L Balant, et al.
Pageof 17

Showing results (81-90 of 163) with videos related to

Sort By:
Pageof 17
Biochemical Pharmacology|December 1, 1987
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiencyP Dayer, T Kronbach, M Eichelbaum, et al.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|February 4, 1992
[Therapy compliance. A matter of concern in clinical medicine]J Fabre, J P Assal, L Balant, et al.
British Journal of Clinical Pharmacology|January 1, 1996
Contribution of monoaminergic modulation to the analgesic effect of tramadolJ A Desmeules, V Piguet, L Collart, et al.
Schweizerische Medizinische Wochenschrift|October 16, 1982
[Prevalence of arterial hypertension according to national origin. Epidemiologic survey of the personnel of the international organizations in Geneva]P Laravoire, A Baczko, J Fabre, et al.
European Journal of Clinical Pharmacology|December 14, 1999
Drug-drug interactions of new active substances: mibefradil exampleJ C Krayenbühl, S Vozeh, M Kondo-Oestreicher, et al.
Cancer Research|December 16, 1998
Association between lung cancer and microsomal epoxide hydrolase genotypesS Benhamou, M Reinikainen, C Bouchardy, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolP Dayer, L Balant, A Kupfer, et al.
European Journal of Clinical Pharmacology|January 1, 1983
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agentsP Dayer, L Balant, A Küpfer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Metabolic genetic polymorphisms and susceptibility to lung cancerC Bouchardy, S Benhamou, N Jourenkova, et al.
Pharmaceutica Acta Helvetiae|January 1, 1982
[Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency]D Dupont, P Dayer, L Balant, et al.
Pageof 17